BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 24444563)

  • 21. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.
    Hu JL; Hu XL; Han Q; Guo AY; Wang CJ; Wen YY; Cang SD
    Gene Ther; 2017 Jul; 24(7):392-398. PubMed ID: 28436941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
    Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
    Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
    PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
    Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
    Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
    Kang S; Ju W; Kim JW; Park NH; Song YS; Kim SC; Park SY; Kang SB; Lee HP
    Exp Mol Med; 2006 Jun; 38(3):320-4. PubMed ID: 16819291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
    Gao H; Ge RC; Liu HY; Wang Y; Yan S
    Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
    Xu ZC; Cai HZ; Li X; Xu WZ; Xu T; Yu B; Zou Q; Xu L
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.